celecoxib oral

In patients with dMMR or MSI-H locally advanced colorectal cancer, neoadjuvant toripalimab plus celecoxib significantly increased the proportion of patients attaining pathological complete response compared with toripalimab monotherapy, with a similar safety profile. These findings support further investigation of this combination strategy in larger phase 3 trials.

P=N/A, N=165, Not yet recruiting, Beijing Tiantan Hospital

P1/2, N=112, Recruiting, Shanghai 6th People's Hospital | Not yet recruiting --> Recruiting

P1, N=6, Terminated, HonorHealth Research Institute | Trial completion date: Dec 2026 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; The study was terminated early per the recommendation of the Data and Safety Monitoring Board (DSMB) after a planned interim analysis met pre-specified criteria for futility.

This exploratory pharmacodynamic biomarker analysis identifies three 3-cytokine panels associated with prognostic risk stratification in metronomic chemotherapy for metastatic gastrointestinal cancer. As this single-arm trial cannot distinguish prognostic from predictive value, findings are hypothesis-generating. Prospective external validation is required before clinical translation, and exploration in combination with immune checkpoint inhibitors is warranted.

Leveraging clinical feasible RNA-seq and TMB analysis, our model exhibits robust predictive efficacy of ICB response in multiple cancers, enabling subtype-tailored therapeutic combinations to improve immunotherapy response.

P1/2, N=6, Not yet recruiting, Shanghai 6th People's Hospital

The system is constructed using celecoxib (CXB)-loaded poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles and subsequently camouflaging them with mesenchymal stem cell membranes with high CXCR4 expression...This dual modulation of the chemokine network significantly improves the therapeutic efficacy of CAR-T cells against solid tumors. Our approach represents a promising strategy for advancing CAR-T cell therapy toward clinical applications for soild tumors.

By integrating genetic causal inference, in vitro experiments, and network pharmacology, our study systematically reveals that celecoxib may exert therapeutic effects by targeting against cervical cancer by targeting NEU1 and modulating CD25 on CD45RA+ CD4+ non-regulatory T cell-related immune pathways. This finding highlights both the novelty and the translational potential of this approach.

P2/3, N=80, Not yet recruiting, Odense University Hospital

P1/2, N=75, Completed, University of Southern California | Unknown status --> Completed

Moreover, intervention with the PTGS2 inhibitor celecoxib counteracted the tumor-promoting functions of OTX1 and demonstrated tumor-suppressive effects in in vivo OS models. Herein, results demonstrate that OTX1 drives OS malignant progression by transcriptionally activating PTGS2, which in turn modulates apoptosis- and invasion-related molecules. Targeting the OTX1/PTGS2 axis may represent a promising therapeutic strategy for OS, particularly in high-risk patients with aberrant OTX1 expression.